The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | On-body isatuximab delivery in myeloma: improving convenience and administration
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the emerging role of the on-body injector (OBI) formulation of isatuximab in multiple myeloma treatment. Dr Ocio highlights the potential advantages of the device, including greater convenience, reduced administration time, fewer infusion-related reactions, and the possibility of outpatient or future self-administration. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
